参考文献
(在框内滑动手指即可浏览)
[1] Heit JA.The epidemiology of venous thromboembolism in the community[J].Arterioscler Thromb Vasc Biol,2008,28(3):370-372.
[2] Stein PD,Matta F.Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused[J].Am J Med,2012,125(5):465-470.
[3] Emadi A,Streiff M.Diagnosis and management of venous thromboembolism: an update a decade into the new millennium[J].Arch Iran Med,2011,14(5):341-351.
[4] Silverstein MD,Heit JA,Mohr DN,et al.Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study[J].Arch Intern Med,1998,158(6):585-593.
[5] Zhenguo Zhai. VTE risk profiles and prophylaxis in medical and surgical inpatients[J].Chest,2019,155(1):114-122.
[6] Howell WH,Holt E. Two new factors in blood coagulation heparin and proantithrombin[J]. Am J Physiology,1918,47:328-333.
[7] Howell WH,McDonald CH. Note on the effect of repeated intravascular injections of heparin[J]. John Hopkins Hospital,1930,46:365-371.
[8] Schofield FW. Damaged sweet clover: the cause of a new disease in cattle simulating hemorrhagic septicemia and blackleg[J].J Am Vet Assoc,1924,64:553-575.
[9] Link KP.The discovery of dicumarol and its sequels[J].Circulation,1959,19(1):97-107.
[10] Holmes RW,Love J.Suicide attempt with warfarin,a bishydroxycoumarin-like rodenticide[J].J Am Med Assoc,1952,148(11):935-937.
[11] 张福先.周围血管疾病的溶栓与抗凝治疗[J].中国实用外科杂志,2006,26(10):801-803.
[12] Holm HA,Ly B,Handeland GF,et al.Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin[J].Haemostasis,1986,16:30-37.
[13] Crafoord C. Preliminary report on post-operative treatment with heparin as a preventive of thrombosis[J]. Acta Chir Scand,1937,79:407-426.
[14] Murray GDW,Best CH. Heparin and thrombosis: the present situation[J]. JAMA,1938,110:118-122.
[15] Barritt DW,Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial[J].Lancet,1960,1(7138):1309-1312.
[16] 张福先. 抗凝与出血管理中的争议与共识[J].中国实用外科杂志,2017,37(12):1328-1331.
[17] Letter to the Editors- in-chief. Management of major bleeding outcomes under antithrombotic therapy in real-life[J].Thrombosis Res,2020,187:28-31.
[18] Kimachi M,Furukawa TA,Kimachi K,et al.Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease[J].Cochrane Database Syst Rev,2017,11(11):CD011373.
[19] Ha JT,Neuen BL,Cheng LP,et al.Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis[J].Ann Intern Med,2019,171(3):181-189.
[20] Hoolwerf EW,Kraaijpoel N,Büller HR,et al.Direct oral anticoagulants in patients with liver cirrhosis: A systematic review[J].Thromb Res,2018,170:102-108.
[21] Violi F,Vestri A,Menichelli D,et al.Direct oral anticoagulants in patients with atrial fibrillation and advanced liver disease: an exploratory meta-analysis[J].Hepatol Commun,2020,4(7):1034-1040.
[22] Chan N,Sager PT,Lawrence J,et al.Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?[J].Am Heart J,2018,199:59-67.
[23] Hohnloser SH,Fudim M,Alexander JH,et al.Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight[J].Circulation,2019,139(20):2292-2300.
[24] Chan N,Sobieraj-Teague M,Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues[J]. Lancet,2020,396(10264):1767-1776.
[25] Najidh S,Versteeg HH,Buijs JT.A systematic review on the effects of direct oral anticoagulants on cancer growth and metastasis in animal models[J].Thromb Res,2020,187:18-27.
[26] Rocha AL,Trevisan RLB,Duffles LF,et al.Inhibitory effects of dabigatran etexilate, a direct thrombin inhibitor, on osteoclasts and osteoblasts[J].Thromb Res,2020,186:45-53.
[27] Ridker PM,Everett BM,Thuren T,et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease[J].N Engl J Med,2017,377(12):1119-1131.
[28] Tardif JC,Kouz S,Waters DD,et al.Efficacy and safety of low-dose colchicine after myocardial infarction[J].N Engl J Med,2019,381(26):2497-2505.
[29] Saliba W,Warwar A,Kotler A,et al.Association of factor V activity with risk of venous thromboembolism and atherothrombotic cardiovascular events: A retrospective population-based cohort study[J].Thromb Res,2018,168:14-19.